Perampanel is a highly selective, noncompetitive AMPA-type glutamate receptor antagonist currently in development for the treatment of partial seizures in patients with epilepsy. After oral ...

AMPA receptors are present throughout the ... the clinical development of RAP-219 for the treatment of drug-resistant focal epilepsy, peripheral neuropathic pain and bipolar acute mania, including ...

AMPA receptors are present throughout the brain ... the clinical development of RAP-219 for the treatment of drug-resistant focal epilepsy, peripheral neuropathic pain and bipolar acute mania, ...

AMPA receptors are present throughout the brain ... the clinical development of RAP-219 for the treatment of drug-resistant focal epilepsy, peripheral neuropathic pain and bipolar acute mania, ...

In the PET trial, RAP-219 achieved and exceeded target receptor ... focal epilepsy, with topline results expected in mid-2025. About RAP-219RAP-219 is a clinical-stage AMPA receptor negative ...

Additionally, the data provide further support for the dosing regimen selected for our ongoing Phase 2a trial in focal epilepsy ... TARPγ8 associated AMPA receptors to significantly enhance ...

Additionally, the data provide further support for the dosing regimen selected for our ongoing Phase 2a trial in focal epilepsy.” A total of four Phase 1 trials have ... compelling translational ...

(Nasdaq: RAPP), please note the references to the AMPA ... target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...

(Nasdaq: RAPP), please note the references to the AMPA ... target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy ... focal epilepsy, with topline results expected in mid-2025. RAP-219 is a clinical-stage AMPA receptor negative ...